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Glucose and lipids stimulate the gut-hormones glucagon-like peptide (GLP)-1, GLP-2 and
glucose-dependent insulinotropic polypeptide (GIP) but the effect of these on human post-
prandial lipid metabolism is not fully clarified.
Objective
To explore the responses of GLP-1, GLP-2 and GIP after a fat-rich meal compared to the
same responses after an oral glucose tolerance test (OGTT) and to investigate possible
relationships between incretin response and triglyceride-rich lipoprotein (TRL) response to
a fat-rich meal.
Design
Glucose, insulin, GLP-1, GLP-2 and GIP were measured after an OGTT and after a fat-rich
meal in 65 healthy obese (BMI 26.5–40.2 kg/m2) male subjects. Triglycerides (TG), apoB48
and apoB100 in TG-rich lipoproteins (chylomicrons, VLDL1 and VLDL2) were measured
after the fat-rich meal.
Main OutcomeMeasures
Postprandial responses (area under the curve, AUC) for glucose, insulin, GLP-1, GLP-2,
GIP in plasma, and TG, apoB48 and apoB100 in plasma and TG-rich lipoproteins.
PLOS ONE | DOI:10.1371/journal.pone.0145890 January 11, 2016 1 / 15
OPEN ACCESS
Citation: Matikainen N, Björnson E, Söderlund S,
Borén C, Eliasson B, Pietiläinen KH, et al. (2016)
Minor Contribution of Endogenous GLP-1 and GLP-2
to Postprandial Lipemia in Obese Men. PLoS ONE 11
(1): e0145890. doi:10.1371/journal.pone.0145890
Editor: Kathrin Maedler, University of Bremen,
GERMANY
Received: October 26, 2015
Accepted: December 9, 2015
Published: January 11, 2016
Copyright: © 2016 Matikainen et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This paper was supported by grants from
Helsinki University Central Hospital EVO‐funds,
Finnish Diabetes Research Foundation, Academy of
Finland (grants 266286 and 272376), European
Foundation for the Study of Diabetes, Sigrid Juselius
Foundation, Foundation Leducq France, Swedish
Research Council, Swedish Heart Lung Foundation,
Diabetes Research Wellness Foundation,
Sahlgrenska University Hospital ALF grant, Swedish
Diabetes Foundation, the NovoNordisk Foundation
and the EU project RESOLVE.
Results
The GLP-1, GLP-2 and GIP responses after the fat-rich meal and after the OGTT correlated
strongly (r = 0.73, p<0.0001; r = 0.46, p<0.001 and r = 0.69, p<0.001, respectively). Glucose
and insulin AUCs were lower, but the AUCs for GLP-1, GLP-2 and GIP were significantly
higher after the fat-rich meal than after the OGTT. The peak value for all hormones
appeared at 120 minutes after the fat-rich meal, compared to 30 minutes after the OGTT.
After the fat-rich meal, the AUCs for GLP-1, GLP-2 and GIP correlated significantly with
plasma TG- and apoB48 AUCs but the contribution was very modest.
Conclusions
In obese males, GLP-1, GLP-2 and GIP responses to a fat-rich meal are greater than follow-
ing an OGTT. However, the most important explanatory variable for postprandial TG excur-
sion was fasting triglycerides. The contribution of endogenous GLP-1, GLP-2 and GIP to
explaining the variance in postprandial TG excursion was minor.
Introduction
Enteroendocrine cells in the gastrointestinal tract may act as nutritional sensors because they
secrete a variety of peptide hormones, which regulate energy balance, satiety and metabolism in
response to oral nutrient ingestion. These hormones include glucagon-like peptide (GLP)-1
secreted by L-cells in distal small intestine and glucose-dependent insulinotropic polypeptide
(GIP) secreted by K-cells [1]. Both peptides stimulate insulin secretion, and together they are
responsible for the incretin effect, i.e., the augmentation of insulin secretion observed when glu-
cose is administered orally rather than intravenously [2, 3]. Although they act similarly to stim-
ulate insulin secretion via specific receptors expressed by the β-cell, they differentially influence
glucagon secretion from the α-cells [1], with GLP-1 inhibiting and GIP stimulating secretion.
Like GLP-1, GLP-2 is a product of preproglucagon and is secreted in parallel and in equimo-
lar amounts with GLP-1 from the L-cells in response to carbohydrate and lipid ingestion. How-
ever, unlike GLP-1, GLP-2 does not stimulate insulin secretion, but increases glucagon secretion
[4, 5], while having a powerful stimulating effect on intestinal growth, mucosal integrity and
nutrient absorption. An appetite regulating effect through central nervous system GLP-2 recep-
tors [5, 6] has also been proposed. These properties provide the background for the therapeutic
use of degradation resistant GLP-2 in small bowel syndrome and other intestinal malabsorption
states [5], but the physiological roles of GLP-2 in humans is far from fully understood.
Defects in both secretion and insulinotropic actions of GLP-1 and GIP appear as early signs
of insulin resistance characterizing the metabolic syndrome [7, 8]. Another early and central
metabolic defect in the metabolic syndrome is the overproduction of both hepatic VLDL and
intestinal chylomicron particles because of an impaired suppressive action of insulin. Such
abnormalities lead to the development of an atherogenic dyslipidemia, i.e., fasting and post-
prandial hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol levels and high
levels of small low-density lipoprotein (LDL) particles [9–11]. Therefore, even before develop-
ment of hyperglycemia, increased levels of both TG-rich lipoprotein (TRL) remnants and
small dense LDL particles contribute to accelerated atherosclerosis [12].
Interestingly, GLP-1, GLP-2 and GIP have all been implicated in lipid homeostasis. In
rodent models, GLP-1 decreases apolipoprotein (apo) B48 production in the intestine [13].
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Indirect evidence derived from the pharmacological use of GLP-1 mimetics or dipeptidyl pepti-
dase (DPP) 4-inhibitors strongly suggests that GLP-1, and possibly GIP, reduce intestinal and,
in some studies, also hepatic postprandial TRL particles [14, 15]. A kinetic study by Xiao et al.
[16] also demonstrated inhibition of apoB48 production by Exenatide, a GLP-1 receptor ago-
nist. Interestingly, GLP-2 may have an opposite role by promoting intestinal lipid absorption
via induction of CD36/fat acid translocase, as well as by promoting packaging and secretion of
apoB48-containing chylomicrons in rodents [17]. In humans, much less is known about the
combined physiological effects of the intestinal hormones on regulation of postprandial lipid
metabolism, although pharmacological doses of GLP-2 injected subcutaneously in humans
were recently reported to rapidly increase apoB48 and TG in TRL, as well as TG levels in
plasma during constant intraduodenal feeding [18].
Here we report the endogenous responses of GLP-1, GLP-2 and GIP following a fat-rich
mixed meal test and after a standard oral glucose tolerance test (OGTT) in male overweight
subjects with a wide range of fasting TG levels. The purpose of this study was to compare the
magnitude and time sequence of GLP-1, GLP-2 and GIP responses elicited by a fat-rich mixed
meal test to explore the possible concerted action of these intestinal hormones in the regulation
of postprandial lipid metabolism.
Materials and Methods
Study subjects
We studied 65 overweight healthy men from our Fructose intervention protocol (Clinical Tri-
als NCT01445730) carried out in Helsinki, Naples and Gothenburg. The subjects were
recruited via a newspaper advertisement. Males with large waist (>94 cm) and body mass
index (BMI) between 26.5 and 40 kg/m2 who had been weight stable for at least the last 3
months were included in the study. Each subject underwent a physical examination and labora-
tory tests to exclude cardiovascular disease, uncontrolled hypertension, type 2 diabetes, hepatic
diseases, renal, gastroenteral, thyroid or haematological abnormalities. Subjects with regular
daily alcohol consumption (greater than two drink equivalents per day) (i.e., 20 g pure alcohol)
were excluded from the study. None of the subjects used medication or hormones affecting
lipoprotein metabolism. The study design was approved by the local Ethics committees at Uni-
versity of Helsinki, Finland, University of Gothenburg, Sweden and University of Naples, Italy
and each subject gave written informed consent before participation in the study. All the sam-
ples were collected in accordance with the Declaration of Helsinki.
Each subject underwent an oral fat tolerance test, served as a fat-rich mixed meal (in the
text referred as a “fat-rich meal”), and a standard OGTT on separate days within 2 weeks. The
participants abstained from alcohol and physical exercise for two days before each examina-
tion. Each subject was asked to keep a 3-day food diary to ensure that they followed an ordinary
isocaloric diet during the study.
After a 12-h fast, subjects received a fat-rich meal consisting of bread, butter, cheese, ham,
boiled eggs, fresh red pepper, low fat (1%) milk, orange juice and tea or coffee (63 g carbohy-
drates, 56 g fat and 40 g protein). The fat-rich meal contained 927 kcal. Blood samples were
drawn before and 30, 60, 120, 180 and 240 minutes after the meal for determination of glucose,
insulin, GLP-1, GLP-2 and GIP as well as for determination of lipid and lipoproteins. During
the test, only water was allowed ad libitum and the subjects remained physically inactive.
In addition, a 75 g OGTT was performed after an overnight fast. The subjects consumed 75
g of glucose and blood sampling was done before and 5, 10, 30, 60, 90, 120, 180 and 240 min-
utes after the OGTT for determination of glucose, insulin, GLP-1, GLP-2 and GIP.
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Biochemical analysis
Fasting and postprandial concentrations of glucose (hexokinase method, Roche Diagnostic
Gluco-quant, Mannheim, Germany) and insulin (electrochemiluminescence with Roche sand-
wich immunoassay on a Cobas autoanalyzer) were measured after the fat-rich meal and the
OGTT. Adiponectin was measured by an enzyme-linked immunosorbent assay (R&D Systems,
Inc., Minneapolis, USA) [19]. GIP, GLP-1 and GLP-2 plasma concentrations were measured
after ethanol extraction (70% vol/vol, final concentration), as described. GIP and GLP-1 were
measured using C-terminally directed assays, which detect both the intact peptide and the pri-
mary (N-terminally truncated) metabolite; such assays therefore can be designated as “total”,
and can be used to reflect the rate of secretion [20]. For GIP [21], we used antiserum code #
80867, which reacts fully with GIP 3–42, but not with GIP 8000, whose chemical nature and
relationship to GIP secretion is uncertain. Plasma concentrations of GLP-1 were measured
[22] using antiserum code no. 89390, which is specific for the amidated C-terminus of GLP-1.
This antiserum reacts fully with GLP-1 9-36amide (and with the small amounts of pancreatic
GLP-1 1-36amide), but does not cross-react with major proglucagon fragment from the pan-
creas. For both assays sensitivity was below 1 pmol/l and intrassay coefficient of variation
below 6% at 20 pmol/l. GLP-2 concentrations were measured employing antiserum code no.
92160 [23]. The antiserum is directed against the N-terminus of GLP-2 and therefore measures
only fully processed GLP-2 of intestinal origin. Sensitivity for the assay is below 2 pmol/l, and
intra-assay coefficient of variation below 6%.
Isolation of lipoproteins
Lipoprotein fractions [chylomicrons (Sf>400), large VLDL1 particles (Sf60–400) and smaller
VLDL2 particles (Sf20–60)] were separated by density gradient ultracentrifugation. All of these
fractions contain both apoB48 and apoB100 particles that were further analyzed using
SDS-PAGE, as previously described [24]. TG and cholesterol concentrations in total plasma
and lipoprotein fractions were analyzed by automated enzymatic methods using the Konelab
60i analyzer (Thermo Electron Corporation, Vantaa, Finland. Fasting and postprandial
apoB48 levels (Elisa kit, Shibayagi Co. Ltd, Shibukawa, Gunma, Japan) were measured in
plasma.
Statistical analyses and calculations
Statistical analyses were performed using GraphPad Prism 6 forWindows (GraphPad Software,
Inc., San Diego, CA). Data are presented as mean ± SEM, SD or range. HOMA-IR and
HOMA-IS indices were calculated as described previously [25]. Skewed data were either trans-
formed to natural logarithms when indicated, or analyzed using nonparametric tests. The area
under curve (AUC) and incremental AUC (i.e., the AUC above the fasting concentration) for
postprandial variables were calculated according to the trapezoid rule. Only AUCs are shown to
simplify the results, because fasting values for glucose, insulin, and incretins were similar before
fat-rich meal and OGTT. Correlations were calculated using Spearman´s rank test. A p
value< 0.05 was considered statistically significant. Relative importance analysis was performed
in order to estimate howmuch the different measured variables (including GLP-1, GLP-2 and
GIP) contributed to explaining the variance in the parameters of interest (in this case TG plasma
AUC, apoB48 AUC and TG chylomicron AUC). If all variables were uncorrelated, this quantifi-
cation would be equivalent to the variable’s individual R-squared value. However, since this was
not the case we used the method for relative importance analysis proposed by Lindeman, Mer-
enda and Gold [26]. The analysis was performed using the R package "relaimpo" [https://cran.r-
project.org/web/packages/relaimpo/relaimpo.pdf]. Since many parameters were measured,
Do Endogenous GLP-1 and GLP-2 Contribute to Postprandial Lipemia in Obese Men?
PLOSONE | DOI:10.1371/journal.pone.0145890 January 11, 2016 4 / 15
variable selection was performed before the relative importance analysis. Ten variables (GLP-1,
GLP-2, GIP, insulin AUC, glucose AUC, fasting TG, liver fat, visceral fat, adiponectin and
HbA1c) was chosen as variables in common between the three separate analyses with TG
plasma AUC, apoB48 AUC and TG chylomicron AUC as response variables respectively. In
addition, the top five most correlating variables for each response variable were included. Thus,
these five variables varied between each analysis. This design was chosen in order to clarify how
GLP-1, GLP-2 and GIP affected postprandial TRL metabolism relative to other common vari-
ables and relative to the top correlating parameters for each response variable.
Results
Baseline characteristics
The characteristics of the 65 study subjects are summarized in Table 1. Fasting concentrations
of glucose, insulin, GLP-1, GlP-2 and GIP were essentially similar before the OGTT and the
test meal, as also illustrated in Fig 1.
Relationships between fasting incretins with glycemic and lipid levels in
the fasting state
There were no correlations between fasting concentrations of GLP-1, GLP-2 or GIP with BMI,
nor with concentrations of fasting glucose, HOMA-IS, fasting plasma TG and apoB48 or
Table 1. Baseline characteristics. Subject characteristics and fasting concentrations of glucose, insulin,
GLP-1, GLP-2 and GIP before fat-rich meal and OGTT. Data are mean ± standard deviation.
Mean ± SD Range
Age, years 48.7 ± 10.2 21−65
BMI, kg/m2 30.8 ± 3.0 26.5−40.2
Waist, cm 109 ± 8.2 94.5−130.5
Hip, cm 108 ± 8.6 91−137
S-cholesterol, mmol/L 4.96 ± 0.83 3.46−7.05
S-LDL-cholesterol, mmol/L 3.28 ± 0.78 1.94−5.3
S-triglycerides, mmol/L 1.50 ± 0.89 0.34−4.52
S-HDL-cholesterol, mmol/L 1.18 ± 0.32 0.5−2.04
HbA1c, % 5.38 ± 0.32 4.7−6.0
Homa-IR 3.20 ± 0.25 0.46−9.9
Homa-IS, % 121 ± 44.8 32−258
Adiponectin 4.64 ± 2.54 1.4−12.3
Fat-rich meal
P-glucose, mmol/L 5.37 ± 0.45 4.3−6.3
P-insulin, pmol/L 82.2 ± 52.5 11−261
P-GLP-1, pmol/L 13.6 ± 5.41 7−37
P-GLP-2, pmol/L 14.7 ± 6.05 7−46
P-GIP, pmol/lL 11.2 ± 4.89 3−29
OGTT
P-glucose, mmol/L 5.43 ± 0.50 4.5−6.5
P-insulin, pmol/L 98.4 ± 59.0 19−293
P-GLP-1, pmol/l 14.5 ± 5.63 7−31
P-GLP-2, pmol/L 17.2 ± 9.07 4−44
P-GIP, pmol/L 13.9 ± 18.7 3−154
doi:10.1371/journal.pone.0145890.t001
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fasting TG, apoB48 and apoB100 in chylomicron or VLDL1. Fasting GLP-1 but not GLP-2 nor
GIP correlated, weakly but significantly, with fasting insulin (r = 0.298, p = 0.017) and
HOMA-IR (r = 0.33, p = 0.008).
Glucose, insulin and incretin responses after fat-rich mixed meal and
OGTT
First, we explored the impact of the fat-rich meal (56 g fat) and the OGTT on GLP-1, GLP-2
and GIP concentrations as well as on glucose and insulin concentrations (Fig 1). Glucose
(AUC 1338 mmol/L×min after fat-rich meal and 1578 mmol/L×min after OGTT, p<0.001)
and insulin (AUC 79507 mmol/L×min after fat-rich meal and 96911 mmol/L×min after
OGTT, p = 0.0011) responses were significantly lower after fat-rich meal as compared to
OGTT. In contrast, AUC responses for GLP-1, GLP-2 and GIP were significantly (1.4, 1.7 and
2.1 times) higher after the fat-rich meal than after OGTT (Table 2).
The times to peak concentrations for glucose (30 min) and insulin (60 min) were similar
after fat-rich meal and OGTT and returned to baseline levels at 180 minutes. However, the
time of peak concentrations of GLP-1, GLP-2 and GIP during fat-rich meal occurred later, at
120 min, with concentrations remaining elevated at 240 minutes. The AUC responses for GLP-
1, GLP-2 and GIP measured after the fat-rich meal correlated with their corresponding AUC
Fig 1. Responses of glucose, insulin, GLP-1, GLP-2 and GIP after fat-rich meal (open circles) and OGTT (black circles). Data showmean ± SEM.
Stars indicate significant (p-value < 0.05) difference between fat-rich meal and OGTT for a given time point.
doi:10.1371/journal.pone.0145890.g001
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responses assessed after the OGTT (S1 Fig). Furthermore, GLP-1 and the GLP-2 AUCs during
both the fat-rich meal and the OGTT were significantly correlated, as shown in S2 Fig. GLP-1
and GLP-2 are released in a molar ratio of 1:1 but have different half-lives [27]. To study the
relationship between GLP-1 and GLP-2 after the OGTT and after the fat-rich meal we calcu-
lated GLP-1/GLP-2 ratios. We observed no significant changes in ratios up to 90 minutes
between the two experiments but as GLP-2 values remained elevated at 120 and 240 min after
the fat rich meal compared to those after the OGTT, the GLP-1/GLP-2 ratio was significantly
lower at 120 and 240 minutes after the fat rich meal (Fig 1).
Postprandial responses of lipids and lipoproteins after fat rich mixed
meal
After the test meal, plasma TG and apoB48 levels, as well as TG, apoB48 and apoB100 in chylo-
micron and VLDL1, increased significantly from fasting concentrations (S1 Table). S3 Fig dis-
plays the curves for plasma total TG and apoB48. The peak concentrations for both serum TG
and apoB48 were observed at the 240 min time point and thereafter started to decline. Notably,
plasma apoB48 rose more rapidly than TG levels, with an early peak at 120 min which was not
evident in the plasma TG curve, and remained elevated up to 240 min. The maximum concen-
trations of TG and apoB48 were reached in chylomicrons and VLDL1 fractions at 240 minutes
(data not shown).
Relationships between incretin AUCs vs. TRLs during the fat-rich meal
Weak positive correlations were observed between glucose and insulin AUC after the fat-rich
meal and triglycerides and apoB48 in plasma, chylomicrons and VLDL1 (S2 Table). Fasting
adiponectin correlated negatively with triglycerides in plasma, chylomicrons and VLDL1. We
observed no relationships between adiponectin and GLP-1, GLP-2 or GIP.
To study the relationship between incretin and postprandial TRL responses during the fat
rich meal, we first calculated the Spearman correlations between GLP-1, GLP-2, GIP and TG,
apoB48 and apoB100 AUC responses in plasma, chylomicrons and VLDL1 (Fig 2). Signifi-
cant, positive correlations were observed between GLP-1 as well as GLP-2 AUCs and GIP
AUCs with AUCs for TG and apoB48 in chylomicrons, whereas their relationships with
plasma TG and apoB48 levels were less consistent. Overall however, these correlations were
moderate to weak and as shown in Fig 2, the r-squared values for these correlations were
close to zero. Furthermore, the results from the relative importance analysis (Fig 3) shows
that GLP-1, GLP-2 and GIP contributed very little to explaining the variance in TG plasma
AUC, apoB48 AUC and TG chylomicron AUC. Insulin AUC, glucose AUC, adiponectin,
Table 2. Incretin responses after fat-rich meal and OGTT. Areas under curve (AUC) for glucose, insulin, GLP-1, GLP-2 and GIP after the fat-rich meal
and after the OGTT calculated between 0–240 minutes. Data are mean ± standard deviation. The given p-value shows differences between fat-rich meal and
OGTT.
Fat-rich meal OGTT
Glucose (mmol/L × min) 1338 ± 165 1578 ± 280***
Insulin (pmol/L × min) 79507 ± 53934 96911 ± 66490***
GLP-1 (pmol/L × min) 6070 ± 2116 4498 ± 1547***
GLP-2 (pmol/L × min) 8413 ± 3414 4925 ± 2300***
GIP (pmol/L × min) 15125 ± 5968 7375 ± 2946***
*** p<0.001
doi:10.1371/journal.pone.0145890.t002
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liver fat, visceral fat and HbA1c did not either display large individual contributions to
explaining the variance in postprandial TG excursion. The individual largest explanatory var-
iable for postprandial TG excursion among the commonly measured clinical risk factors was
fasting triglycerides.
Fig 2. Correlation between incretins and postprandial lipid responses. Correlations between areas under curve (AUC) for GLP-1, GLP-2 and GIP with
plasma TG, apoB48 in the chylomicron fraction, and triglycerides in the chylomicron fraction after the fat-rich meal.
doi:10.1371/journal.pone.0145890.g002
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Fig 3. Relative importance analysis.Contribution of each variable for explaining (A) the plasma TG AUC
(B) the TG-chylomicron AUC and (C) the apoB48 AUC after the fat-rich meal. For every plot 15 variables are
shown. Ten variables including GLP-1, GLP-2 and GIP (to the left in each plot) are shared between (A), (B)
and (C). Five variables to the right hand side in the graphs vary between (A), (B) and (C). These five were
chosen as they correlate most strongly with the response variable in question and thus provide a relative
importance reference to the other ten variables.
doi:10.1371/journal.pone.0145890.g003
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Discussion
Here we report endogenous responses of GLP-1, GLP-2 and GIP after both fat-rich meal and
OGTT in healthy obese males and to show that the responses of these three metabolic gut hor-
mones were highly correlated with each other. We also show that the responses of these gut
hormones were significantly higher and more prolonged after the fat-rich meal than in
response to the OGTT, although postprandial plasma glucose and insulin levels remained
lower than during the OGTT. After the fat-rich meal, concentrations of GLP-1, GLP-2 and
GIP continued to increase up to 240 min compared to early peaks observed at 30 minutes dur-
ing the OGTT. Notably, the time pattern of glucose and insulin responses after the fat-rich
meal mimicked the time pattern after the OGTT, but the responses of both glucose and insulin
were as expected higher after the OGTT. The responses of both TG and apoB48 in chylomi-
crons after the fat-rich meal correlated significantly positively with both GLP-1 and GLP-2
responses despite the fact that GLP-1 and GLP-2 are reported to have divergent effect on intes-
tinal lipid metabolism [28]. However, the correlations were weak, as the low r-squared values
indicate. Large variation in postprandial TRL AUCs was observed between subjects with simi-
lar GLP-1 and GLP-2 responses. In addition, the relative importance analysis revealed that
GLP-1, GLP-2 and GIP AUCs did not explain much of the variation in TRL AUCs. Our data
thus provide no evidence for a seminal role of endogenously produced GLP-1, GLP-2 or GIP
on postprandial metabolism of TRL particles but highlight the predictive role of fasting triglyc-
erides as previously documented [12].
Both carbohydrate and fat ingestion are physiological stimuli for secretion of gastrointestinal
hormones [29, 30]. We utilized OGTT as a reference test for the fat-rich meal as most of the cur-
rent knowledge on incretin responses is derived fromOGTT performed in healthy subjects as
well as in metabolic diseases. The responses of GLP-1 and GIP after an oral fat challenge have
been reported to be higher than after an intravenous administration at matched plasma TG con-
centrations, suggesting an analogous response of the incretin hormones after an oral lipid load
as seen after OGTT [21]. In addition, Nauck et al reported a strong correlation between GLP-1
and GIP responses of OGTT [31]. In the present study, both GLP-1 and GIP in response to a
fat-rich meal and OGTT increased promptly at 30 minutes, but peaked much later at 120 min-
utes after the fat-rich meal compared to early peaks observed after the OGTT. The overall
responses of GLP-1, GLP-2 and GIP after the fat rich meal were markedly higher than after the
oral glucose challenge. In fact, the response of GIP was about 2-fold higher after the fat-rich
meal than after the OGTT, and the values remained elevated up to 240 minutes, in line with
Vollmer et al who reported that GIP response to a meal test containing 820 kcal (353 kcal from
fat) was markedly higher and prolonged compared to OGTT [32]. These differences may be due
the differences in gastric emptying of the served nutrients that is known to modify the release of
incretin hormones. Indeed, the two tests in our study differed markedly in size, consistency, and
fat content. This likely affected the gastric emptying and thus the slope of the curves in Fig 1.
Fat, protein and carbohydrates stimulate the release of GLP-1 and GIP in healthy humans.
We opted to use a fat-rich meal containing all three nutrients as this represents a more physio-
logically relevant meal than serving pure olive oil, a protein mix [33], lipid emulsions [21] or
constant intraduodenal feeding (18). As the fat-rich meal contained a significant amount of
protein (40 g), we cannot exclude that part of the sustained responses of GLP-1 and GIP could
be linked to protein ingestion [34]. In addition the high energy (927 kcal for the fat-rich meal
compared to 300 kcal for the OGTT) and high fat content of the meal may have influenced the
absorption of nutrients and thus also the release of incretin hormones.
A wealth of evidence from both human and animal studies demonstrate that incretin-based
therapies not only improve glycemic control, but also improve the lipid profiles in patients with
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T2D [13, 16, 29, 35–37]. Infusion of synthetic GLP-1 in pharmacological doses has been shown
to reduce intestinal lymph flow, handling and absorption of dietary fat and intestinal secretion
of apoB48 resulting in reduction of postprandial triglycerides in rats and in human [38]. Data
from recent intestinal lipoprotein kinetic studies suggest that the action of GLP-1 on the produc-
tion and release of intestinal TRL particles is inhibitory, leading to the lowering of postprandial
triglyceride excursions [16, 37, 39]. The elegant design of the lipoprotein kinetic studies allows
us to conclude that exenatide, a GLP-1 receptor agonist, has a direct effect on intestinal lipopro-
tein production beyond its actions on gastric emptying and nutrient absorption [28]. Likewise,
the suppression of postprandial lipid and apoB48 responses to fat feeding has been confirmed in
animal studies [13]. Our observation that GLP-1 response to fat-rich meal explained only a
minor part in the variation of postprandial responses of triglycerides or apoB48 in chylomicrons
seems to contradict a primary role for GLP-1 in the regulation of chylomicron release.
GLP-2 is secreted from intestinal L cells together with GLP-1 in a 1:1 molar ratio in response
to nutrient intake [30]. GLP-2 has trophic actions in intestine and its major effects are to
enhance intestinal cell growth, intestinal blood flow as well as increase absorption of major
macronutrients [40]. It should be recognized that GLP-2R is not expressed in enterocytes.
Thus the potential actions of GLP-2 on intestinal lipid metabolism have remained mostly
unnoticed. However, a recent review highlighted that GLP-2 may have divergent effects from
GLP-1 on intestinal lipid metabolism [28]. Intravenous infusion of GLP-2 during a solid meal
stimulated postprandial responses of triglyceride compared to placebo in healthy humans most
likely due to enhanced lipid absorption [41]. When GLP-2 was injected acutely subcutaneously,
it increased the intestinal secretion of apoB48 and chylomicrons [42]. In this elegant study,
Dash et al. demonstrated that acute injection of GLP-2 enhanced release of pre-synthesized
apoB48 stored in the gut. In our study, we observed very rapid increases of both TRL triglycer-
ides and apoB48 after the fat-rich meal and the chylomicron triglyceride and apoB48 AUC cor-
related significantly but weakly with the responses of GLP-2. In Syrian hamster and mice,
GLP-2 has been reported to enhance fat absorption and intestinal release of TRLs and increase
apoB48 responses to fat feeding [17, 43, 44]. Our data from the relative importance analyses
suggest that GLP-2, like GLP-1, can provide only limited explanatory power for the variation
of chylomicron responses to fat-rich meal. The data does not exclude that GLP-1 and GLP-2
may modify intestinal lipid metabolism, however it indicates that exogenously administered
pharmacological doses of GLP-1 and GLP-2 analogues may have diverse action on some path-
ways compared with endogenously released hormones leaving the contribution of GLP-1 and
GLP-2 on intestinal chylomicron metabolism still open.
Dietary lipids are either assembled into chylomicrons and secreted into lymphatic vessels,
or stored in the intestinal cells as lipid droplets for the storage of fat to be mobilized later [45].
Interestingly, we observed a rapid increase of plasma apoB48 in response to fat-rich meal, but
the response of plasma triglycerides was delayed and less robust at the early time point after
the fat-rich meal. This early release of apoB48 agrees well with the observation by Dash et al.
that GLP-2 injection increased TRL triglyceride and apoB48 levels already at 30 minutes [42].
The authors concluded that GLP-2 has a special effect on the mobilization of prestored apoB48
from enterocytes [17, 28, 42]. Recently the preferential release of triglycerides from intestinal
storage pool by GLP-2 injection intraperitoneally was confirmed in Syrian golden hamster
[44]. The results are consistent with the concept of the “second meal effect” that is considered
to reflect the utilization of storage pool lipids derived from previous meals for chylomicron
release [46, 47]. This concept becomes important when we face successive fat rich meals in our
daily food consumption. An important question is whether the amount of ingested fat is a
determinant of intestinal fat stores and postprandial lipemia leading to the accumulation of
thermogenic remnants in the circulation.
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Lipid digestion has been shown to release long chain fatty acids (LCFA) that are essential
for lipid sensing, not only in the gut, but also in the tongue taste buds and in the brain [48].
This capacity for fat taste has been proposed to modify intestinal lipid handling via rapid incre-
tin secretion after meal ingestion. The fact that both GLP-1 and GLP-2 concentrations were
increased at 30 and 60 minutes after the fat-rich meal, preceding the increase of apoB48 at 60
and 120 minutes and TG at 120 minutes, might indicate that these responses of GLP-1 and
GLP-2 relate to fat tasting and may elicit the release of pre-stored apoB48 and chylomicrons
from lipid droplets in enterocytes.
The strength of our study is that all three metabolic hormones were measured during both a
fat-rich meal as well as a standard OGTT. This, together with a comprehensive analysis of TRL
particles, allowed us to follow the dynamics of both chylomicrons from the intestine and liver-
derived VLDL1 after a fat-rich meal. The study has some limitations, it is observational and the
nutritional challenges were given as single loads. We did not have a metabolically healthy lean
cohort for comparison, meaning that the results cannot be extrapolated to different cohorts.
Additionally, the conclusions are based primarily on advanced statistical analysis, so appropri-
ate intervention studies are needed to dissect out the actions of the individual hormones on
lipid metabolism. Thus, we cannot unveil the molecular mechanisms behind the responses of
GLP-1, GLP-2 and GIP to fat ingestion. In conclusion, our data do not support a decisive role
for the three intestinal hormones in the regulation of postprandial lipid metabolism after a fat-
rich meal. It is important to emphasize that the endogenous responses of GLP-1, GLP-2 and
GIP reported in this study, do not have to correspond to responses after pharmacological inter-
vention targeting GLP-1 or GLP-2.
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